Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen

Epigenetics

Volumn 7, Issue 7, 2012, Pages 701-709

  Jeschke, Jana ^a,b,c   Van Neste, Leander ^d,e   Glöckner, Sabine C ^a,f   Dhir, Mashaal ^a   Calmon, Marilia Freitas ^a,b   Deregowski, Valérie ^e   Van Criekinge, Wim ^d,e   Vlassenbroeck, Ilse ^e   Koch, Alexander ^d   Chan, Timothy A ^g   Cope, Leslie ^b   Hooker, Craig M ^b   Schuebel, Kornel E ^b   Gabrielson, Edward ^a   Winterpacht, Andreas ^c   Baylin, Stephen B ^b   Herman, James G ^b   Ahuja, Nita ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d GHENT UNIVERSITY   (Belgium)

^e MDxHealth   (Belgium)

^f UNIVERSITY OF REGENSBURG   (Germany)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Biomarker; Breast cancer; Detection; Functional hypermethylome screen; Prognosis

Indexed keywords

BIOLOGICAL MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CDO1 GENE; CKM GENE; CONTROLLED STUDY; CPG ISLAND; CRIP1 GENE; DNA METHYLATION; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE FREQUENCY; GENE SILENCING; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GREM1 GENE; HOXD1 GENE; HUMAN; HUMAN TISSUE; KL GENE; MAJOR CLINICAL STUDY; NDRG2 GENE; OVERALL SURVIVAL; PROMOTER REGION; TAC1 GENE;

EID: 84863797091     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.20445     Document Type: Article

References (32)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212-236. PMID:21685461; http://dx.doi.org/10.3322/caac.20121.
2. Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314:268-274. PMID:16959974; http://dx.doi.org/10.1126/science.1133427.
3. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318:1108-1113. PMID:17932254; http://dx.doi.org/10.1126/science.1145720.
4. Akashi M, Koeffler HP. Li-Fraumeni syndrome and the role of the p53 tumor suppressor gene in cancer susceptibility. Clin Obstet Gynecol 1998; 41:172-199. PMID:9504235; http://dx.doi.org/10.1097/00003081-199803000-00024.
5. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266:66-71. PMID:7545954;http://dx.doi.org/10.1126/science.7545954.
6. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. Tp53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007; 26:2157-165;PMID:17401424; http://dx.doi.org/10.1038/sj.onc.1210302.
7. Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, et al.; Breast Cancer Susceptibility Collaboration (UK). ATM mutations that cause ataxiatelangiectasia are breast cancer susceptibility alleles. Nat Genet 2006; 38:873-875. PMID:16832357; http://dx.doi.org/10.1038/ng1837.
8. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378:789-792; PMID:8524414; http://dx.doi.org/10.1038/378789a0.
9. Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer 2007; 7:545-53. PMID:17585334; http://dx.doi.org/10.1038/nrc2173.
10. Carey LA. Through a glass darkly: advances in understanding breast cancer biology 2000-2010. Clin Breast Cancer 2010; 10:188-195. PMID:20497917; http://dx.doi.org/10.3816/CBC.2010.n.026.
11. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature2002; 415:530-536. PMID:11823860; http://dx.doi.org/10.1038/415530a.
12. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365:671-679. PMID:15721472.
13. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351:2817-2826. PMID:15591335; http://dx.doi.org/10.1056/NEJMoa041588.
14. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007; 25:1239-1246. PMID:17401012; http://dx.doi.org/10.1200/JCO.2006.07.1522.
15. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349:2042-2054. PMID:14627790; http://dx.doi.org/10.1056/NEJMra023075.
16. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivationof the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343:1350-1354. PMID:11070098; http://dx.doi.org/10.1056/NEJM200011093431901.
17. Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008; 358:1118-1128. PMID:18337602; http://dx.doi.org/10.1056/NEJMoa0706550.
18. Schuebel KE, Chen W, Cope L, Glöckner SC, Suzuki H, Yi JM, et al. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet 2007; 3:1709-1723. PMID:17892325; http://dx.doi.org/10.1371/journal.pgen.0030157.
19. Glöckner SC, Dhir M, Yi JM, McGarvey KE, VanNeste L, Louwagie J, et al. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res 2009; 69:4691-4699;PMID:19435926; http://dx.doi.org/10.1158/0008-5472.CAN-08-0142.
20. Hoque MO, Kim MS, Ostrow KL, Liu J, Wisman GB, Park HL, et al. Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res 2008; 68:2661-2670. PMID:18413733; http://dx.doi.org/10.1158/0008-5472.CAN-07-5913.
21. Ordway JM, Budiman MA, Korshunova Y, Maloney RK, Bedell JA, Citek RW, et al. Identification of novel high-frequency DNA methylation changes in breast cancer. PLoS One 2007; 2:1314. PMID:18091988;http://dx.doi.org/10.1371/journal.pone.0001314.
22. Ostrow KL, Park HL, Hoque MO, Kim MS, Liu J, Argani P, et al. Pharmacologic unmasking of epigenetically silenced genes in breast cancer. Clin Cancer Res 2009; 15:1184-1191. PMID:19228724; http://dx.doi.org/10.1158/1078-0432.CCR-08-1304.
23. Fujikane T, Nishikawa N, Toyota M, Suzuki H, Nojima M, Maruyama R, et al. Genomic screening for genes upregulated by demethylation revealed novel targets of epigenetic silencing in breast cancer. Breast Cancer Res Treat 2010; 122:699-710. PMID:19859801; http://dx.doi.org/10.1007/s10549-009-0600-1.
24. McGarvey KM, Van Neste L, Cope L, Ohm JE, Herman JG, Van Criekinge W, et al. Defining a chromatin pattern that characterizes DNA-hypermethylated genes in colon cancer cells. Cancer Res 2008; 68:5753-5759. PMID:18632628; http://dx.doi.org/10.1158/0008-5472.CAN-08-0700.
25. Zhang W, Glöckner SC, Guo M, Machida EO, Wang DH, Easwaran H, et al. Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res 2008; 68:2764-2772;PMID:18413743; http://dx.doi.org/10.1158/0008-5472.CAN-07-6349.
26. Hill VK, Ricketts C, Bieche I, Vacher S, Gentle D, Lewis C, et al. Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. Cancer Res 2011; 71:2988-2999. PMID:21363912; http://dx.doi.org/10.1158/0008-5472.CAN-10-4026.
27. Hoque MO, Feng Q, Toure P, Dem A, Critchlow CW, Hawes SE, et al. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol 2006; 24:4262-4269. PMID:16908936; http://dx.doi.org/10.1200/JCO.2005.01.3516.
28. Yan PS, Perry MR, Laux DE, Asare AL, Caldwell CW, Huang TH. CpG island arrays: an application toward deciphering epigenetic signatures of breast cancer. Clin Cancer Res 2000; 6:1432-1438. PMID:10778974.
29. Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002; 416:552-556. PMID:11932749; http://dx.doi.org/10.1038/416552a.
30. Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J Mol Biol 1987; 196:261-282;PMID:3656447; http://dx.doi.org/10.1016/0022-2836(87)90689-9.
31. Brandes JC, Carraway H, Herman JG. Optimal primer design using the novel primer design program: MSPprimer provides accurate methylation analysis of the ATM promoter. Oncogene 2007; 26:6229-6237. PMID:17384671; http://dx.doi.org/10.1038/sj.onc.1210433.
32. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93:9821-9826. PMID:8790415; http://dx.doi.org/10.1073/pnas.93.18.9821.